Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating semorinemab in prodromal to mild Alzheimer's disease was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Semorinemab (Semorinemab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Alzheimer's Disease | Phase 2 | Status: TERMINATED | Results posted: 2022-03-16